Compare ZDAI & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDAI | LITS |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | Hong Kong | United States |
| Employees | 33 | 4 |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 40.8M |
| IPO Year | N/A | N/A |
| Metric | ZDAI | LITS |
|---|---|---|
| Price | $4.28 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 476.1K | 358.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.95 |
| 52 Week High | $6.56 | $3.03 |
| Indicator | ZDAI | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 47.69 |
| Support Level | $0.39 | $0.98 |
| Resistance Level | $6.56 | $1.16 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 63.50 | 58.62 |
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.